These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30134806)

  • 1. Inhibition of HDAC6 activity in kidney diseases: a new perspective.
    Ke B; Chen Y; Tu W; Ye T; Fang X; Yang L
    Mol Med; 2018 Jun; 24(1):33. PubMed ID: 30134806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease.
    Batchu SN; Brijmohan AS; Advani A
    Clin Sci (Lond); 2016 Jun; 130(12):987-1003. PubMed ID: 27154743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
    Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
    Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
    Cebotaru L; Liu Q; Yanda MK; Boinot C; Outeda P; Huso DL; Watnick T; Guggino WB; Cebotaru V
    Kidney Int; 2016 Jul; 90(1):90-9. PubMed ID: 27165822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciliopathies: Does HDAC6 Represent a New Therapeutic Target?
    Yu F; Ran J; Zhou J
    Trends Pharmacol Sci; 2016 Feb; 37(2):114-119. PubMed ID: 26651415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury.
    Tang J; Shi Y; Liu N; Xu L; Zang X; Li P; Zhang J; Zheng X; Qiu A; Zhuang S
    Clin Sci (Lond); 2018 Feb; 132(3):339-359. PubMed ID: 29358506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
    Zhang XH; Qin-Ma ; Wu HP; Khamis MY; Li YH; Ma LY; Liu HM
    J Med Chem; 2021 Feb; 64(3):1362-1391. PubMed ID: 33523672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation.
    Zhang QQ; Zhang WJ; Chang S
    Front Immunol; 2023; 14():1168848. PubMed ID: 37545520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2-Methylquinazoline derivative 23BB as a highly selective histone deacetylase 6 inhibitor alleviated cisplatin-induced acute kidney injury.
    Hao Y; Guo F; Huang Z; Feng Y; Xia Z; Liu J; Li L; Huang R; Lin L; Ma L; Fu P
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
    Wu H; Yang K; Zhang Z; Leisten ED; Li Z; Xie H; Liu J; Smith KA; Novakova Z; Barinka C; Tang W
    J Med Chem; 2019 Aug; 62(15):7042-7057. PubMed ID: 31271281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
    Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
    Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
    Brindisi M; Saraswati AP; Brogi S; Gemma S; Butini S; Campiani G
    J Med Chem; 2020 Jan; 63(1):23-39. PubMed ID: 31415174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Development of Novel HDAC6 Isoform-selective Inhibitors.
    Zhao Y; Liang T; Hou X; Fang H
    Curr Med Chem; 2021; 28(21):4133-4151. PubMed ID: 33176627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury.
    Shi Y; Xu L; Tang J; Fang L; Ma S; Ma X; Nie J; Pi X; Qiu A; Zhuang S; Liu N
    Am J Physiol Renal Physiol; 2017 Mar; 312(3):F502-F515. PubMed ID: 28052874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
    Cosenza M; Pozzi S
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30096875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
    He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
    Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
    Wang XX; Wan RZ; Liu ZP
    Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of histone deacetylase inhibitors on kidney disease.
    Chun P
    Arch Pharm Res; 2018 Feb; 41(2):162-183. PubMed ID: 29230688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted inhibition of histone deacetylase 6 in inflammatory diseases.
    Ran J; Zhou J
    Thorac Cancer; 2019 Mar; 10(3):405-412. PubMed ID: 30666796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.